artemether Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antimalarial agents, artemisinin related compounds 245 71963-77-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • artemether
  • artemos
  • artenam
  • artesaph
  • dihydroartemisinin methyl ether
  • falcidol
  • gvither
  • malartem
  • beta-Artemether
An artemisinin derivative that is used in the treatment of MALARIA.
  • Molecular weight: 298.38
  • Formula: C16H26O5
  • CLOGP: 3.05
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 0
  • TPSA: 46.15
  • ALOGS: -2.81
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.28 g O
0.12 g P
0.28 g R
0.28 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.70 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 58 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
April 7, 2009 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haemolytic anaemia 111.61 40.94 22 230 9820 46675990

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haemolytic anaemia 106.49 46.86 21 135 9989 29942333

Pharmacologic Action:

SourceCodeDescription
ATC P01BE02 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
ANTIMALARIALS
Artemisinin and derivatives, plain
ATC P01BF01 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTIPROTOZOALS
ANTIMALARIALS
Artemisinin and derivatives, combinations
FDA EPC N0000175482 Antimalarial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000962 Antimalarials
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
CHEBI has role CHEBI:38068 antimalarials

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chloroquine Resistant Plasmodium Falciparum Malaria indication
Torsades de pointes contraindication 31722008
Hypokalemia contraindication 43339004
Bradycardia contraindication 48867003
Prolonged QT interval contraindication 111975006
Hypomagnesemia contraindication 190855004
Congenital long QT syndrome contraindication 442917000

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
C7D6T3H22J UNII
4028721 VUID
N0000178417 NUI
D02483 KEGG_DRUG
C0052429 UMLSCUI
CHEBI:195280 CHEBI
D8Z PDB_CHEM_ID
CHEMBL566534 ChEMBL_ID
DB06697 DRUGBANK_ID
D000077549 MESH_DESCRIPTOR_UI
68911 PUBCHEM_CID
6458 INN_ID
9955 IUPHAR_LIGAND_ID
18343 RXNORM
18572 MMSL
d05142 MMSL
009714 NDDF
420578008 SNOMEDCT_US
420661005 SNOMEDCT_US
4028721 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
COARTEM HUMAN PRESCRIPTION DRUG LABEL 2 0078-0568 TABLET 20 mg ORAL NDA 28 sections
COARTEM HUMAN PRESCRIPTION DRUG LABEL 2 76413-154 TABLET 20 mg ORAL NDA 27 sections